Aponvie : first intravenous P/neurokinin-1 (NK) receptor antagonist - It was a brilliant idea that it significantly enhanced the efficacy of the generic drug by changing the route of administration. - Aponvie’s fast onset of action, and half-life in human brain and convenience for patients (compliance perspective) seem very strong. - However, the market penetration of Aponvie will be deecided by..